Showing posts sorted by date for query BACTERIOPHAGE. Sort by relevance Show all posts
Showing posts sorted by date for query BACTERIOPHAGE. Sort by relevance Show all posts

Thursday, July 16, 2026

Scientists find hidden individuality in viral infections

A new study reveals that viruses exhibit substantial differences in how they shape the fate of host cells, with implications for ecology, evolution and biotechnology


University of Maryland






An international team of researchers developed a new way to uncover hidden differences in how viruses infect and destroy individual microbial cells—solving a biological puzzle that has persisted for more than 80 years.

For decades, researchers have focused on answering a key question: What happens inside a single infected cell before that cell bursts open to release a new generation of viruses? To answer the question, they typically measure two traits—how long the virus takes to rupture the cell and how many new viruses are released—which are estimated as population averages, masking potentially important differences from one infected cell to the next.

In a new University of Maryland-led study embargoed until publication at 2 p.m. ET on July 15, 2026, in the journal Science Advances, researchers showed for the first time that they could accurately predict hidden cell-to-cell variation in infection outcomes using population-level cell measurements.

“Individual infections do not unfold the same way,” said the paper’s senior author Joshua Weitz, a professor of biology at UMD with a joint appointment in the University of Maryland Institute for Health Computing. “Successfully quantifying that variation at the level of a single cell opens the door to developing predictive models of how viruses can be used therapeutically to confront drug-resistant pathogens and how viruses transform environmental health.”

A precise prediction model

The researchers used a mathematical modeling framework developed over the past decade by Weitz’s group to analyze how viral populations accumulate over multiple rounds of infection. Leveraging subtle signals in large-scale patterns, the model inferred what was happening inside individual cells—including variation in the timing of the cell rupture when new viruses are released.

To test those predictions, collaborators in the lab of Debbie Lindell, a professor of biology at the Technion - Israel Institute of Technology, developed a single-cell experimental assay that directly measured infection outcomes in individual cells.

The experiments used bacteriophages, also known as phages, which are viruses that infect bacteria. Though invisible to the naked eye, phages are among the most abundant biological entities on Earth and play a crucial role in shaping microbial populations, nutrient cycling and ecosystem health. Phages are also increasingly evaluated and used therapeutically to target and clear infections caused by antibiotic-resistant bacteria.

The researchers focused on a marine phage-bacteria pair: a specific type of phage that infects abundant open ocean bacteria that fix carbon via photosynthesis. Viral infections of these cyanobacteria impact carbon cycling at global scales, making them ecologically important.

The results showed that the mathematical model’s predictions were strikingly accurate. The researchers found that the timing of cell rupture varied substantially from one infected cell to another in this phage-bacteria pair.

“Our findings contribute to solving an 80-year-old mystery on the sources of phenotypic variability in bacteriophages and advance the understanding of a core principle of the biology of viruses,” said the paper’s first author Marian Dominguez-Mirazo, who recently earned her Ph.D. in quantitative biosciences from the Georgia Institute of Technology.

Timing is (almost) everything

The researchers also uncovered a surprising new relationship between how long a virus remains inside a cell and how many offspring it produces.

Though earlier studies of synthetically controlled viral infections proposed that virus production would quickly level off as infections progressed, Weitz noted that his team didn’t see that happen.

“That’s not what we found,” said Weitz, who also holds the Clark Leadership Chair in Data Analytics at UMD. “Instead, we saw a piecewise linear relationship. Viruses generally kept producing offspring in proportion to the duration of infection, suggesting that viruses burst cells at different moments, often long before they run out of usable resources.”

That finding helps explain another mystery first identified by Nobel laureate Max Delbrück in his pioneering work on bacteriophage biology in the 1940s: Why does the number of viruses released from infected cells vary so dramatically?

The new work shows that much of that variation can be explained by differences in how long a virus takes to rupture the cell, which suggests that viral timing, both its average and its variability, may itself be shaped by evolution.

The study bridges microbiology, ecology, evolutionary biology and mathematical modeling, Weitz said, “offering a new way to understand not just average viral behavior, but the hidden diversity of infection outcomes occurring one cell at a time.”

Beyond advancing principles of virology, these findings provide an important new quantitative tool for studying and predicting the spread of viral infections in systems where direct single-cell measurements are difficult or impossible.

“Because viruses that infect microbes influence everything from ocean ecosystems to bacterial disease dynamics, understanding the hidden variation of viral traits could improve predictive models in environmental science, microbiology and emerging therapeutic applications,” Weitz said.

***

The paper, “Inferring single-cell heterogeneity of bacteriophage lysis-associated life-history traits from population-scale dynamics,” by Marian Dominguez-Mirazo, Ran Natan, Shay Kirzner, Debbie Lindell, and Joshua Weitz, is in press. It will be published in Science Advances on July 15, 2026, under doi 10.1125/sciadv.6456.

This research was supported by the Simons Foundation Life Sciences Program (Award Nos. 735081, 529554 and 722153). This article does not necessarily reflect the views of this organization.

Monday, June 15, 2026

 

Study reveals 45 new toxins produced by bacteria associated with foodborne infections




Computational tools were used to analyze the genetic material of 6,165 samples from 149 different types of Salmonella enterica subspecies





Fundação de Amparo à Pesquisa do Estado de São Paulo






 Researchers at the University of São Paulo (USP) in Brazil have discovered 45 new toxins produced by Salmonella bacteria, some of which are associated with foodborne infections. The study was conducted at the Center for Research in Bacterial and Bacteriophage Biology (B3 RIDC) and was published in the journal PLOS Biology. It shows that these substances primarily act in the competition among microorganisms for space and resources. The study also suggests that these substances may inspire the development of new antibiotics, in-depth studies with humans, and biotechnological applications in the future.

The B3 is one of the Research, Innovation, and Dissemination Centers (RIDCs http://cepid.fapesp.br/en) supported by FAPESP.

To investigate the microscopic arsenal used by the pathogen, the team analyzed genetic data from Salmonella and its type VI secretion system (T6SS), which is a spear-like system that the bacterium uses to inject effectors, such as toxins that interfere with the functioning of other cells, into the environment or directly into competing microorganisms. Using computational tools, the team analyzed the genetic material of 6,165 samples from 149 different serovars of Salmonella enterica, identifying potential toxins and comparing sequences among different bacteria. They also inferred their functions based on similarities to known proteins.

A total of 128 types of toxins were identified, 45 of which were very different from any known toxin and had never before been described by science. “This result implies that the diversity of bacterial toxins and antitoxins worldwide is very high, with new varieties emerging or diverging radically from known related variants,” explains Robson Francisco de Souza, leader of the bioinformatics group at the Laboratory of Protein Structure and Evolution at USP, a researcher at the B3 RIDC, and one of the authors of the study.

The identified molecules act in different ways. Some compete with other bacteria, while others affect eukaryotic cells, including those of fungi, yeasts, algae, and even mammals. “It’s possible that some of them play a direct role in human infections, but to confirm that hypothesis, we’d need to identify which strain carries the genes targeting eukaryotes and experimentally assess their effect on cells and infection,” the researcher notes.

This diversity is also reflected in the distribution of the effectors discovered among the different Salmonella groups. The article shows that each group has a unique combination of molecules secreted by the T6SS. This suggests that the bacterium selects and maintains specific effectors based on environmental pressures. “The evolution of these systems and this diversity are driven by both gene recombination, which frequently occurs to generate and activate new toxins, and by natural selection, which, in a scenario of biological conflict, fuels an arms race among bacteria,” states Souza.

The data also suggest that Salmonella subgroups collected from natural environments have a greater number of effectors than those collected from patients. This indicates that toxin diversity increases in contexts with a greater variety of competitors. “This happens because, as new challenges and adversaries emerge, the microorganism needs to develop new tools to excel in these disputes over resources,” the researcher explains.

According to Souza, these findings should improve our understanding of bacterial competition strategies and pave the way for new clinical and biotechnological applications. “We may even have applications that we can’t yet anticipate,” he predicts. “We believe this because some of our previous work has shown that important eukaryotic proteins originated from bacterial toxins,” he adds, highlighting the potential of these compounds in different biological contexts.

Souza emphasizes that the field is far from exhausted. “Bacteria such as Salmonella, Acinetobacter, and other organisms still offer opportunities to understand the role of these toxins in ecological interactions,” he states. “We’re continuing to invest in developing software and pipelines to automate this type of analysis and expand the investigation to new lineages, such as archaea and lesser-known bacteria, which present even more opportunities for this type of discovery,” he concludes.

About São Paulo Research Foundation (FAPESP)
The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at www.fapesp.br/en and visit FAPESP news agency at www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe

Tuesday, June 02, 2026

Gladstone launches Center for PhAIge Therapy to harness AI in the fight against drug-resistant infections



The center, funded by an NIH grant, will become one of three national centers dedicated to accelerating the development of phage therapy.



Gladstone Institutes

Gladstone Investigators Katie Pollard, Melanie Ott, and Seth Shipman 

image: 

A team of scientists at Gladstone Institutes—including Katie Pollard (left), Melanie Ott (center), Seth Shipman (right), and Sukrit Silas (absent from the photo)—will lead one of three new national centers dedicated to accelerating the development of phage therapy.

view more 

Credit: Photo: Michael Short/Gladstone Institutes




SAN FRANCISCO—When a bacterial infection stops responding to antibiotics, doctors have few options to treat it. Phages—viruses that naturally infect and kill bacteria—have long intrigued clinicians as a potential weapon against these infections. But translating these tiny bacteria hunters into drugs has been slow and unreliable.

Now a new effort, powered by engineering and artificial intelligence, could change that.

Gladstone Institutes has received an initial award of $2 million from the National Institute of Allergy and Infectious Diseases (NIAID), with additional funding of up to a total of $10 million available over the proposed 5-year project period. This grant will establish the Center for PhAIge Therapy, a research center that will develop new phage-based treatments for antibiotic-resistant bacterial infections.

The five-year grant makes Gladstone one of three institutions across the country selected to lead this coordinated effort. Together, the new Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP) will advance the therapeutic use of phages.

The Center for PhAIge Therapy will be directed by Gladstone Investigator Seth Shipman, PhD, with projects and core components led by an interdisciplinary team of other Gladstone scientists.

“Phages have the potential to treat drug-resistant infections, but for patients to benefit from that potential, we need to be able to predict which phage to use for which patient, and design phages that are more effective than what we have today,” says Shipman. “That’s what this center is designed to do.”

Tackling Critical Threats to Modern Medicine

Every year, about 5 million deaths around the world are associated with antibiotic-resistant infections.

People with weakened immune systems, including those with cancer who are receiving immune therapies, are particularly vulnerable because they rely heavily on effective antibiotics. But antibiotic resistance is no longer confined to high-risk patients—it’s increasingly affecting the broader hospital population as well.

Among the leading causes of these deaths are major hospital “superbugs” called the ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

These bacterial species appear on the World Health Organization’s list of priority pathogens. They are considered critical threats to modern medicine not only because they resist drugs, but they swap defense mechanisms and quickly adapt after being exposed to new antibiotics.

Given that phages have evolved the ability to kill bacteria in distinct and targeted ways, they have attracted growing interest as a potential weapon against ESKAPE pathogens and other antibiotic-resistant infections.

So far, despite promising results in individual patients, phage therapy has remained difficult to use at a larger scale, in part because it has required so much trial and error for each patient.

The new Center for PhAIge Therapy will build the preclinical tools and models needed to overcome this obstacle and make phages a more reliable treatment for infections.

Gladstone scientists have developed AI tools to predict which phages can work against a particular strain of bacteria, but the models are lacking the right data to make the predictions accurate. So, the researchers will run massive experiments using engineered phages and bacteria to better understand, step by step, how bacteria are killed.

“The goal of our center is to generate an unprecedented amount of data and train AI models to identify the right phage for any patient’s infection,” says Shipman.

Deploying Phages Against Drug-Resistant Pathogens

Shipman’s lab has already developed tools to precisely edit phage genomes in a highly effective way, giving them the ability to engineer new phages.

The Center for PhAIge Therapy will allow the team to build on that technology and develop new tools to accelerate research on how best to optimize and deploy phages against ESKAPE pathogens.

They will build high-throughput assays to measure how individual parts of phages contribute to their activity against bacteria. The project will ultimately generate the data needed to rationally design and select phages effective against Klebsiella pneumoniae.

In healthcare settings, Klebsiella pneumoniae can cause serious infections—including pneumonia, bloodstream infections, and meningitis—among patients on ventilators or intravenous catheters. These bacteria are becoming increasingly resistant to antibiotics, even the last lines of defense used against bacterial infections, and drive over 600,000 deaths per year.

In parallel to Shipman’s work, Gladstone Investigator Sukrit Silas, PhD, will characterize how Klebsiella pneumoniae strains vary in their susceptibility to phages, with the goal of identifying phage combinations most likely to work against specific strains.

Powering both projects will be close collaborations with Katie Pollard, PhD, director of the Gladstone Institute of Data Science and Biotechnology, and Melanie Ott, MD, PhD, director of the Gladstone Infectious Disease Institute.

Pollard will lead the development of new algorithms to predict the compatibility of phage-bacteria pairs and to optimize natural phages into drugs. Using human lung organoids that more closely mimic human tissues than traditional animal models, Ott’s team will study how the body’s environment impacts phage behavior and treatment outcomes, something that can’t be captured in conventional laboratory models.

“What excites me about this collection of projects is that we’re creating a system where the data and the AI build off each other with each iteration,” says Shipman. “We’re not just studying phages using the same methods as in the past; we’re making an infrastructure to rationally predict how we can use phages with success in the future.”

In addition to the Gladstone Center for PhAIge Therapy, the CAPT-CEP network will also be supporting the Center for Phage Pharmaceuticals at Stanford University, which will focus on phage delivery to the lung, and the Pitt Center for Accelerating Phage Therapy at the University of Pittsburgh, which will develop assays for designing and dosing phage cocktails for patients. The three centers will share assays, materials, and data.

###

About the Grant

The Center for PhAIge Therapy at Gladstone will receive $10,239,795 over five years from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The grant P01AI195327 was awarded as a result of the funding call RFA-AI-24-069.

About Gladstone Institutes

Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.

Tuesday, May 19, 2026

 

Establishing a regulatory framework for phage therapy in China




SciOpen
Establishing a regulatory framework for phage therapy in China 

image: 

Current situation and proposed future regulatory frameworks for phage therapy in China. Phage therapy was initially conducted as IITs in China. In May 2026, State Council Decree No. 818 introduced the anticipated clinical translation of phage therapy as a new biomedical technology. In the future, phage therapy in China may be developed through two pathways: as a pharmaceutical product or as a new biomedical technology. Clearer and more science-based regulatory frameworks need to be established through collaborative efforts among regulatory authorities, academia, and industry.

view more 

Credit: hLife





With antimicrobial resistance (AMR) projected to cause more than 39 million deaths and trillions of dollars in economic losses between 2025 and 2050, phage therapy is emerging as a critical solution. In China, phage therapy has already been used across more than 30 hospitals to treat over 500 patients with drug-resistant infections. However, the country currently lacks a dedicated regulatory framework to guide its full clinical translation.

Global phage therapy regulatory frameworks diverge. The European Union (EU, led by Belgium) uses a flexible magistral preparation model, enabling low‑cost, personalized phage therapy without formal drug approval. Meanwhile, the US regulates phages as biologics and provides access via emergency Investigational New Drug (IND) pathways. The UK allows the import of unlicensed products for compassionate use, while Australia is piloting a three‑year GMP exemption for small‑batch, personalized products. Georgia has a long history of phage use but lacks GMP‑compliant production, limiting international acceptance.

In China, phage therapy commenced under investigator‑initiated trial regulations in 2018. Recent policy signals are encouraging: a 2025 NMPA draft guidance indicates that gene‑edited phages may be classified as advanced therapy medicinal products (ATMPs), and State Council Decree No. 818 (effective May 2026) introduces a filing mechanism for phage therapy as a new biomedical technology. Nevertheless, national quality standards and clear approval pathways remain absent.

The research team advocates a three-pillared approach: "standards first, pathway pilots, and industry cultivation." Key recommendations include: (1) National quality guidelines: Develop a technical guideline for phage preparation quality control, building on an existing Shanghai group standard, TSHPPA 028-2024, and ISO/TS 20853:2026. (2) Phase‑appropriate GMP pilot: Offer a 2–3 year GMP exemption or simplified certification for personalized, low‑risk phage preparations that address urgent clinical needs, allowing qualified hospitals to produce them under ethical review while building GMP capacity. (3) Clear product classification: Specify that standard phage products follow the biologics pathway, while gene‑edited phage products may qualify for ATMP classification with expedited policies. (4) Regional centers and reimbursement: Authorize experienced hospitals to establish regional phage therapy centers, supported by integrated pricing, health insurance, and commercial insurance mechanisms.

Dr. Shuai Le emphasizes that comprehensive international frameworks for phage therapy remain underdeveloped. China now has a pivotal opportunity to transition from a regulatory follower to a global frontrunner. By building a high‑quality, context‑appropriate development pathway, China can advance its “Healthy China” initiative while contributing meaningfully to the global fight against AMR.

This research was completed by a joint team from Army Medical University, The Forsyth Institute, CreatiPhage Biotechnology Co., Ltd., and Fudan University. This work was supported by grants from the National Key Research and Development Program of China (2021YFA0911200 to S.L.).

 

About Author:

Shuai Le, Associate Professor at Army Medical University. His laboratory specializes in deciphering the evolutionary battle between phages and their hosts while advancing synthetic phage design and clinical optimization, bridging the gap between basic research and therapeutic applications. A key milestone in his career includes co-leading China’s first personalized trial and first RCT clinical trial on bacteriophage therapy, establishing a foundation for evidence-based phage medicine in the country. Dr. Le has authored over 50 SCI-indexed publications in top-tier journals, including Nature Microbiology, PNAS, The EMBO Journal, and hLife.

Tuesday, May 05, 2026

 

Phage’s deep pockets


Weizmann Institute researchers have identified three new families of proteins that viruses use to disrupt bacterial immune signaling




Weizmann Institute of Science




The genomes of phages – viruses that infect bacteria – are largely composed of “dark matter”: genes that encode proteins whose functions remain unknown. Less than four years ago, a team led by Prof. Rotem Sorek at the Weizmann Institute of Science identified a new type of protein within this viral dark matter and dubbed it a “sponge.” Viral sponge proteins are porous and specialize in trapping molecules within deep pockets – much like a sponge that absorbs water. For phages, however, this sponge serves as a weapon: It traps communication molecules that are essential to bacterial immune systems, allowing the phage to take control of the bacterium and multiply inside it unhindered.

Until recently, very few sponge proteins had been found. Their genetic sequences differ greatly from one another, making them difficult to detect. Now, using an innovative research approach that combines artificial intelligence with experimental biology, researchers in Sorek’s lab have uncovered new families of sponge proteins that disrupt immune communication in bacteria. The findings, published in Science, reveal how viruses silence the immune system’s alarm signals, and shed light on the importance of communication disruption in the billion-year-long war between viruses and bacteria.

In the new study, the researchers examined the structures of sponge proteins identified so far and noticed a recurring architectural pattern that could be used to discover new proteins of this type. “They are all small, composed of several identical subunits and contain deep pockets,” explains Sorek. “These pockets carry a positive electrical charge, allowing them to absorb immune alarm molecules, which are typically negatively charged.”

Insights like these used to have limited practical value, but the AI revolution has changed that. “We realized that with advanced AI tools such as Google’s AlphaFold, we could scan an enormous number of proteins and search for those with positively charged pockets capable of trapping immune molecules,” says Dr. Nitzan Tal, who led the new study in Sorek’s lab. “This allowed us to reveal new functions of phage proteins based solely on their structure.”

The scientists scanned a database of 32 million genes encoding phage proteins, from 2 million phage genomes, and used AlphaFold to predict their three-dimensional structures. “We found more than 120 candidates whose structures matched our criteria, and moved on to experimental testing,” says Tal.

The researchers then tested the effectiveness of each candidate against five bacterial immune systems, using a new method developed by research student Jeremy Garb in Sorek’s lab. The approach enabled the team to perform all the tests simultaneously rather than conducting hundreds of separate experiments. These experiments revealed a new family of sponge proteins that the researchers named Lockin. The AI model predicted that these proteins should consist of six identical subunits arranged in a circular structure resembling flower petals. In collaboration with Prof. Philip J. Kranzusch’s team at the Dana-Farber Cancer Institute in Boston, the researchers determined the structure of one family member using X-ray crystallography, confirming the prediction and deciphering exactly how the immune alarm molecule is captured.

“The huge database of viral proteins we analyzed was mostly obtained from sequencing environmental DNA samples that include a large mixture of phages,” says Sorek. “This allowed us to discover the Lockin proteins, which appeared in hundreds of phages that have never been isolated in the lab.”

Along with AI-based predictions, the researchers used additional innovative strategies. “Romi Hadary, another research student in my lab, noticed that genes that encoded known sponge proteins tend to be fused together in phage genomes,” explains Sorek. “This insight allowed us to identify an additional family of sponge proteins, called Sequestin, based on the fact that their genes are fused to those of known sponges. It goes to show that, even in the age of artificial intelligence, there is still great value in the keen observations of human scientists.”

Yet another protein family discovered in the study, called Acb5, initially puzzled the researchers. “These proteins were very similar to sponge proteins, but we discovered that they not only trap alarm molecules – they also cut them,” says Tal. “This was surprising because they didn’t have the structural features typical of molecular cutting tools. This discovery shows how systematic structural scanning can overturn previous scientific assumptions.”

The protein families identified in this study appear in the genomes of thousands of different phages in nature. The researchers also found that a single phage can carry a broad arsenal of sponges and enzymes that neutralize immune alarm molecules. Together, these findings show that proteins disrupting immune communication give phages a significant advantage in their arms race with bacteria.

“It’s not yet known whether viruses that infect plants, animals and humans also use sponge proteins, but the computational and experimental approach we developed makes it possible to test this,” adds Sorek. “If they do, sponge proteins could become targets for the development of antiviral therapies in the future. Our discovery method doesn’t require prior knowledge of protein function, and it doesn’t rely on spotting similarities in genetic sequences or on growing viruses in the lab. It is therefore a powerful tool for uncovering additional immune-related proteins that share structural patterns.”

Also participating in the study were: Dr. Ilya Osterman, Dr. Gil Amitai, Erez Yirmiya, Dr. Nathalie Béchon, Dr. Dina Hochhauser and Barak Madhala from Weizmann’s Molecular Genetics Department; Renee B. Chang and Miguel López Rivera from the Dana-Farber Cancer Institute, Boston, MA; Roy Jacobson from Weizmann’s Plant and Environmental Sciences Department; Dr. Moshe Goldsmith from Weizmann’s Biomolecular Sciences Department; and Dr. Tanita Wein from Weizmann’s Systems Immunology Department.

Prof. Rotem Sorek’s research is supported by Magnus Konow in honor of his mother Olga Konow Rappaport.

Singapore researchers advance phage therapy in fight against antimicrobial resistance


New study identifies how Mycobacterium abscessus evades treatment and proposes a strategy to overcome resistance




Agency for Science, Technology and Research (A*STAR), Singapore

Bacteriophages attaching to a bacteria cell 

image: 

Findings from A*STAR IDL, NTU Singapore, and NUS provide actionable design principles for more durable phage cocktails, supporting global efforts to develop new countermeasures against drug-resistant infections.

view more 

Credit: 123RF





SINGAPORE – Scientists from A*STAR Infectious Diseases Labs (A*STAR IDL), Nanyang Technological University, Singapore’s Lee Kong Chian School of Medicine (LKCMedicine), the National University of Singapore (NUS), and international collaborators have uncovered how Mycobacterium abscessus – a bacterium that causes serious lung infections – can evade bacteriophage (phage) therapy, and demonstrated a combination strategy to overcome this resistance, offering a pathway towards more effective and durable treatments. The study was published in the Proceedings of the National Academy of Sciences.

Antimicrobial resistance (AMR) is an escalating health challenge that is expected to place growing strain on healthcare systems worldwide. As AMR continues to erode the effectiveness of existing antibiotics – with one in six bacterial infections worldwide now resistant to antibiotics – scientists are accelerating efforts to develop new countermeasures such as phage therapy, which uses viruses to target bacteria. These efforts are important for strengthening global health and infectious disease preparedness.

Understanding How Bacteria Adapt to Survive Treatment

M. abscessus infections are challenging to treat due to their intrinsic resistance to many antibiotics and are increasingly recognised as a significant public health threat.

The researchers found that “smooth” strains of M. abscessus, which are more commonly observed in Asia, respond to phage therapy by switching to a “rough” form, both in the laboratory and pre-clinical models. This transition is linked to mutations in genes responsible for producing glycopeptidolipids, which shape the bacteria’s outer surface.

In other cases, the bacteria resisted phage attack without changing form, instead developing mutations in different surface‑related genes, revealing multiple pathways to resistance.

The team uncovered this resistance mechanism while generating phage‑resistant bacterial mutants to investigate phage‑bacteria interactions.

“These findings reveal an important challenge in developing phage‑based therapies. Although phages can effectively eliminate bacteria, they may also inadvertently make infections more difficult to treat, as seen in the ‘rough’ form,” explained Professor Pablo Bifani, senior author and scientist at LKCMedicine.

Designing More Effective Phage Treatments to Treat AMR Infections

To address this, the team developed a combination therapy targeting both the original “smooth” bacteria and the emerging “rough” variants. This two‑pronged approach proved more effective than a single-phage treatment, pointing toward more robust and longer‑lasting phage therapies for patients.

“What started as a straightforward goal: finding phages that can target M. abscessus smooth strains, led us to the discovery of a clinically relevant resistance mechanism,” said Dr Liew Jun Hao, first author and scientist at A*STAR IDL.

“Phage therapy holds great promise as an alternative treatment for AMR infections, and our findings show that how these treatments are designed is critical. By identifying these ‘escape states’, our study underscores the need for the field to systematically account for bacterial adaptation, so that strategies to counter phage resistance can be built into therapies from the outset, as the threat of AMR continues to grow.”

Associate Professor Albert Yick Hou Lim, Senior Consultant in Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, who was not part of the study team, said: “In clinical settings, infections caused by M. abscessus are challenging to treat due to limited effective therapeutic options. These findings highlight the importance of anticipating how bacteria may respond to treatment. Strategies that account for such adaptive responses, including combination phage therapies, may enhance treatment durability, improve patient outcomes, and better inform clinical management of these complex infections.”

Advancing Novel Therapeutics and Diagnostics Against AMR

By revealing how phage resistance happens, and how it can be mitigated, this study strengthens the ongoing efforts to develop novel therapeutics against AMR.

The findings may also inform future diagnostic and monitoring approaches, such as tracking bacterial form changes and resistance-associated mutations. This could help clinicians tailor treatments and adjust therapeutic strategies more responsively.

Beyond immediate clinical applications, understanding how bacteria evolve under therapeutic pressure is important for infectious disease preparedness. Such insights can inform the design of new therapies that remain effective even as pathogens adapt.

The study contributes to Singapore’s efforts to strengthen capabilities in infectious diseases research and develop solutions to address emerging global health challenges.

– END –

Enclosed:

ANNEX A – Notes to Editor on Research Findings


______________________________________________________________________

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on

Facebook | LinkedIn | Instagram | YouTube | TikTok

 

About A*STAR Infectious Diseases Labs (A*STAR IDL)

A*STAR Infectious Diseases Labs (A*STAR IDL) was established in April 2021 with a mission to be a leading research institute of infectious diseases in antimicrobial resistance, respiratory and vector-borne diseases. A*STAR IDL brings together infectious diseases expertise from across multiple disciplines to drive cutting edge translational infectious diseases research to contribute to Singapore’s national preparedness and defence against the threat of emerging infections. Building upon a robust foundation of our strong biomedical research capabilities and complemented by our globally connected scientific network, A*STAR IDL aims to focus on innovative technologies in infectious disease detection, intervention and prevention with a pathway to impact on health and economic outcomes. https://www.a-star.edu.sg/idlabs

Follow us on

Facebook | LinkedIn | Instagram